Literature DB >> 8924300

Electroencephalograms, clinical observations and the monitoring of neonatal seizures.

A Bye1, D Flanagan.   

Abstract

OBJECTIVE: To identify neonatal seizures and evaluate the efficiency of clinical observations and short duration electroencephalograms (EEG).
METHODOLOGY: Sixty-three neonates were investigated using prolonged video/EEG monitoring. Patients with confirmed seizures were treated with sequential doses of phenobarbitone and, if seizures persisted, phenytoin. The likelihood of correct management if short duration EEG and clinical observations had been employed was determined.
RESULTS: Thirty-two patients had confirmed seizures. After administration of anticonvulsants, clinical observations identified seizures in a mean of 66% (s.d. 7.3%) of the cohort. A 60 min EEG after each stage of phenobarbitone therapy would guarantee electrographic seizure capture in a mean of 76% (s.d. 10%) of the cohort. A 60 min EEG after addition of phenytoin would guarantee capture in 50%.
CONCLUSIONS: An EEG would avoid misdiagnoses in most patients with ambiguous clinical signs. After anticonvulsant infusions, EEG add substantial information to that gained by clinical observations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8924300     DOI: 10.1111/j.1440-1754.1995.tb00872.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  3 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 2.  Neonatal seizures: advances in mechanisms and management.

Authors:  Hannah C Glass
Journal:  Clin Perinatol       Date:  2013-12-12       Impact factor: 3.430

Review 3.  Pharmacological treatment of neonatal seizures: a systematic review.

Authors:  Laurel A Slaughter; Anup D Patel; Jonathan L Slaughter
Journal:  J Child Neurol       Date:  2013-01-14       Impact factor: 1.987

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.